CytomX Therapeutics Inc (NASDAQ:CTMX) has a beta value of 2.12 and has seen 2.4 million shares traded in the last trading session. The company, currently valued at $340.29M, closed the last trade at $2.16 per share which meant it lost -$0.16 on the day or -6.90%% during that session. The CTMX stock price is -43.52% off its 52-week high price of $3.10 and 81.48% above the 52-week low of $0.40. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.22 million shares traded. The 3-month trading volume is 4.92 million shares.
The consensus among analysts is that CytomX Therapeutics Inc (CTMX) is Buy stock at the moment, with a recommendation rating of 1.50. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 4 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.06.
CytomX Therapeutics Inc (NASDAQ:CTMX) trade information
Sporting -6.90%% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the CTMX stock price touched $2.16 or saw a rise of 24.74%. Year-to-date, CytomX Therapeutics Inc shares have moved 67.44%, while the 5-day performance has seen it change -21.45%. Over the past 30 days, the shares of CytomX Therapeutics Inc (NASDAQ:CTMX) have changed 5.88%. Short interest in the company has seen 18.96 million shares shorted with days to cover at 1.78.
Wall Street analysts have a consensus price target for the stock at $5.84, which means that the shares’ value could jump 63.01% from current levels. The projected low price target is $3.25 while the price target rests at a high of $8.0. In that case, then, we find that the current price level is -270.37% off the targeted high while a plunge would see the stock gain -50.46% from current levels.
CytomX Therapeutics Inc (CTMX) estimates and forecasts
The company’s shares have gained 91.15% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -28.49%.
4 analysts offering their estimates for the company have set an average revenue estimate of 19.1M for the current quarter. 4 have an estimated revenue figure of 16.12M for the next ending quarter. Year-ago sales stood 25.11M and 33.43M respectively for this quarter and the next, and analysts expect sales will shrink by -23.95% for the current quarter and -28.49% for the next.
CTMX Dividends
CytomX Therapeutics Inc is expected to release its next earnings report on 2025-May-12 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
CytomX Therapeutics Inc (NASDAQ:CTMX)’s Major holders
Insiders own 0.83% of the company shares, while shares held by institutions stand at 51.02% with a share float percentage of 51.44%. Investors are also buoyed by the number of investors in a company, with CytomX Therapeutics Inc having a total of 82.0 institutions that hold shares in the company. The top two institutional holders are TANG CAPITAL MANAGEMENT LLC with over 7.79 million shares worth more than $9.51 million. As of 2024-06-30, TANG CAPITAL MANAGEMENT LLC held 9.1799% of shares outstanding.
The other major institutional holder is JANUS HENDERSON GROUP PLC, with the holding of over 6.3 million shares as of 2024-06-30. The firm’s total holdings are worth over $7.72 million and represent 7.4245% of shares outstanding.
